Ashurst is advising N M Rothschild & Sons Limited ("Rothschild") and Jefferies International Limited ("Jefferies") on the merger between Al Noor Hospitals Group Plc ("Al Noor") and Mediclinic International Limited ("Mediclinic"). Rothschild is acting as lead financial adviser and co-sponsor, and Jefferies is acting as corporate broker and co-sponsor, in relation to the transaction, which is a reverse takeover of Al Noor for the purposes of the UK Listing Rules.

Al Noor is the largest private integrated healthcare provider in the Emirate of Abu Dhabi with growing presence in other Emirates and Oman. It provides services across the broad spectrum of primary and secondary services, and continues to expand into selective tertiary care. Mediclinic is an international private healthcare group with operations in South Africa, Namibia, Switzerland and the UAE, and an investment in UK private healthcare through a 29.9% interest in LSE-listed Spire Healthcare Group plc.

The combined group will, on a revenue basis, be the third largest private healthcare provider in South Africa, the largest in the UAE and the largest private medical network in Switzerland. The combined group had pro-forma revenue of $4 billion for the fiscal period 2014/15, comprising 46% from Switzerland, 31% from South Africa and 23% from the UAE.

The Ashurst team is being led by corporate partner Tom Mercer, assisted by expertise counsel Caroline Chambers and solicitor Harry Thimont.